Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer

被引：0
|
作者：
Min Huang
M. Catherine Pietanza
Ayman Samkari
James Pellissier
Thomas Burke
Sheenu Chandwani
Fansen Kong
A. Simon Pickard
机构：
[1] Merck & Co.,Centre for Observational and Real
[2] Inc.,world Evidence
[3] Second City Outcomes Research,undefined
来源：
PharmacoEconomics | 2019年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：105 / 116
页数：11
相关论文
共 50 条
  • [41] Quantification of PD-L1 expression in non-small cell lung cancer
    Verma, Vivek
    Chang, Joe Y.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S402 - S404
  • [42] Current PD-L1 immunohistochemistry for non-small cell lung cancer
    Scheel, Andreas H.
    Schaefer, Stephan C.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1217 - 1219
  • [43] PD-L1 expression testing in non-small cell lung cancer
    Teixido, Cristina
    Vilarino, Noelia
    Reyes, Roxana
    Reguart, Noemi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [44] EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
    Murteira, R.
    Ramos, C.
    Cardoso Borges, F.
    Ferreira, M. M.
    Miranda, A.
    da Costa, Alves F.
    VALUE IN HEALTH, 2018, 21 : S15 - S15
  • [45] Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab
    Spiliotaki, Maria
    Neophytou, Christiana Michael
    Vogazianos, Paris
    Stylianou, Ioannis
    Gregoriou, Gregoria
    Constantinou, Andreas Ioannou
    Deltas, Constantinos
    Charalambous, Haris
    MOLECULAR ONCOLOGY, 2023, 17 (05) : 792 - 809
  • [46] PD-L1 status in patients of the Moscow region with non-small cell lung cancer
    Byakhova, M.
    Zavalishina, L.
    Andreeva, Y.
    Tsimafeyeu, I.
    Savelov, N.
    Tjulandin, S.
    Frank, G.
    VIRCHOWS ARCHIV, 2020, 477 : S364 - S364
  • [47] PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy
    Sorensen, Steffen Filskov
    Zhou, Wei
    Dolled-Filhart, Marisa
    Georgsen, Jeanette Baehr
    Wang, Zhen
    Emancipator, Kenneth
    Wu, Dianna
    Busch-Sorensen, Michael
    Meldgaard, Peter
    Hager, Henrik
    TRANSLATIONAL ONCOLOGY, 2016, 9 (01): : 64 - 69
  • [48] Changes in PD-L1 expression in non-small cell lung cancer by immunohistochemical analysis
    Omori, Shota
    Kenmotsu, Hirotsugu
    Abe, Masato
    Watanabe, Reiko
    Sugino, Takashi
    Wakuda, Kazushige
    Ono, Akira
    Taira, Tetsuhiko
    Naito, Tateaki
    Murakami, Haruyasu
    Ohde, Yasuhisa
    Endo, Masahiro
    Akiyama, Yasuto
    Nakajima, Takashi
    Takahashi, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [50] Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
    Zhao, Yanjie
    Shi, Feng
    Zhou, Quan
    Li, Yuchen
    Wu, Jiangping
    Wang, Ruibin
    Song, Qingkun
    MEDICINE, 2020, 99 (45) : E23172
12345